A human liver glucokinase (ATP:D-hexose 6-phosphotransferase, EC 2.7.1.1) cDNA was isolated from a liver cDNA library. This cDNA (hLGLK1) appeared to be full length [2548 base pairs (bp) plus additional poly(A) residues], as its size was consistent with a single 2.8-kilobase (kb) glucokinase mRNA on Northern blot analysis of liver poly(A)+ RNA. The cDNA contained an open reading frame of 1392 bp that predicted a protein of 464 amino acids and a molecular mass of 52 kDa; this protein has 97% identity to rat liver glucokinase. Fourteen residues on the amino terminus of the predicted human liver glucokinase, however, differed completely from those of the predicted rat liver enzyme and could be explained by alternative splicing of a 124-bp cassette exon in human cDNA. A second glucokinase cDNA (hLGLK2), missing the 124-bp cassette exon, was isolated by PCR amplification of human liver cDNA. The hLGLK2 cDNA contained an open reading frame of 1398 bp from an ATG codon at position 164, encoding a predicted protein of 466 residues, 98% identical to the rat enzyme, but different from the predicted protein of hLGLK1 cDNA by 16 amino-terminal residues. In contrast, hLGLK1 cDNA contains multiple initiator codons upstream of the predicted initiator codon at position 294 within the cassette exon. Translation of the two mRNAs in vitro by a reticulocyte lysate system resulted in proteins of the expected size (52 kDa) for both mRNAs; yet hLGLK2 mRNA was translated four to six times more efficiently. These results suggested that the alternative splicing of a cassette exon in hLGLK1 resulted in an mRNA with an upstream initiator codon and reduced function. The relative biological activity of the two isoforms of human glucokinase and their possible developmental and/or metabolic regulation remain to be determined.
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Glucokinase, found exclusively in liver and pancreatic islet beta cells, is one member of a family of hexokinases (ATP:Dhexose 6-phosphotransferase, EC 2.7.1.1) that appear to have a common evolutionary origin (1) (2) (3) (4) . Glucokinase, or hexokinase type IV, is distinguished from the other hexokinases by (i) its low affinity for glucose, with a Km in the physiological range of plasma glucose concentration (5-15 mM), such that glucose phosphorylation maintains a gradient for glucose transport, (ii) by its lack of inhibition by glucose 6-phosphate, and (iii) by its molecular mass of 50 kDa vs. 100 kDa for the other hexokinases. Both tissues that express glucokinase also express a low-affinity, high Km glucose transporter (Glut-2) (5-7), and thus these tissues play an important role in regulation of glucose metabolism. In the liver, the level of glucokinase activity is regulated by hormonal and nutritional factors (8) (9) (10) (11) .
Recent cloning and sequencing of a full-length rat liver glucokinase cDNA provided important direction for studying regulation of expression of this enzyme (12) . The deduced structure predicted a protein of 465 amino acids and a molecular mass of 52 kDa; this sequence was 53% identical to rat brain hexokinase type I. The rat glucokinase gene was subsequently shown to be encoded by 10 exons in 15.5 kilobases (kb) of DNA (11) . Cloning of an islet glucokinase cDNA from rat insulinoma revealed that the mRNA was at least 200 bp longer on the 5' end and that exon 1 was different, resulting in an amino terminus differing by 15 amino acids between the two tissues (13, 14) . Alternative splicing of glucokinase mRNAs has been observed in insulinoma (13) , liver cells (15) , and pituitary cells (16) from rodents.
Defects in glucokinase activity have long been suspected as contributors to the aberrant glucose metabolism of noninsulin-dependent diabetes mellitus in human (for review, see ref. 9 ). Isolation of the rat cDNA (12, 13) gave us the opportunity to screen a human liver cDNA library and isolate glucokinase cDNA clones. We now report the sequence ofan apparent full-length clone* and compare its predicted amino acid sequence to that ofrat glucokinases. In addition, another liver glucokinase mRNA was isolated with a 124-nucleotide deletion, which predicts a protein differing by 16 aminoterminal residues. METHODS cDNA Library Screening, DNA Sequencing, and Data Analysis. A human islet cDNA library (7) was initially screened with a rat-islet glucokinase cDNA (13) , and a 2-kb clone (phIGLK) was isolated. This clone was used to screen a human liver oligo(dT)-primed A ZAP (Stratagene) cDNA library. Inserts were subcloned into Bluescript SK+ (Stratagene) and M13mpl8 and M13mpl9 RF DNA (BRL), and then sequenced in both strands. Questions of compressions were resolved by sequencing with dITP and terminal deoxynucleotidyltransferase, as described (17, 18 
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432-456. Cycle conditions were, after 3-min initial denaturation at 940C, 45 cycles of 940C for 30 sec, and 71'C for 1 min, with a final extension of 720C for 9 min.
Construction of phLGLK2 and in Vitro Translation. The smaller PCR-amplified glucokinase cDNA fragment (see Fig.  2 ) was ligated to the HincII site of M13mp18 and confirmed by sequencing. To construct phLGLK2, the Xba I-Pst I fragment of the phLGLK1, which contained nucleotides 1-367 of hLGLK1, including the 124-bp insertion (see Results), was replaced by the Xba I-Pst I fragment from the M13 clone, missing the insertion. RNA was synthesized by using T3 RNA polymerase (United States Biochemical) and linearized phLGLK1 or phLGLK2 as templates, as described (17 Identification of a Cassette Exon in Genomic DNA. An overall identity of 89% was observed between human and rat liver glucokinase, except for a region of 124 bp not present in the rat cDNA (see Discussion). This 124-bp region in the human cDNA occurred at the junction of exons 1 and 2 in the rat cDNA with 90% identity 3' to exon 2. The predicted protein has no identity to the rat liver protein for the first 14 amino acids, followed by a large region of high identity. To pursue this 5' difference, human glucokinase genomic clones were isolated and sequenced with exon-specific oligonucleotide primers. Based on the structure of the rat genomic glucokinase gene, the 124-bp region corresponded to a cassette exon between exons 1 and 2 (data not shown).
Isolation and Sequencing of a Second Human Glucokinase cDNA. In search for alternative forms of human liver glucokinase, liver RNA was reverse transcribed to cDNA, then analyzed by PCR amplification with glucokinase-specific oligonucleotide primers chosen for exons 1 and 2 of the human glucokinase, based on the genomic structure of the rat glucokinase (see Fig. 1 ,5'-* 3', 34-59; 3' -* 5', 456-432). For cDNA containing the cassette exon a PCR product of 423 bp was predicted, whereas without the cassette exon, a 299-bp product was predicted. Both products were seen (Fig. 2) .
Southern blot analysis and hybridization with 32P-labeled phLGLK1 confirmed that both PCR products were representative of glucokinase mRNA. Hybridization of the blot with an end-labeled oligonucleotide specific for the 124-bp region revealed only the larger 423-bp product (data not shown).
The smaller PCR-amplified glucokinase cDNA fragment was purified, subcloned into M13mpl8, and sequenced. The sequence included the region of flanking primers at nucleotides 34-59 to nucleotides 432-456, but with 124 bp missing relative to the sequence of phLGLK1, as indicated in Fig. 1 Fig.  1 ). Total liver RNA was reverse transcribed, and equal aliquots of cDNA were amplified. Products were separated on a 2.00% agarose gel and stained with ethidium bromide. Lanes: 1, control without RNA; 2-5, human liver cDNA from four different individuals; 6, DNA size markers, 1-kb ladder (BRL; 1 A&g).
smaller proteins (Fig. 3) . Densitometric analysis of the translation product revealed that hLGLK2 mRNA was translated four to six times more efficiently than hLGLK1 mRNA for the predicted 52-kDa glucokinase protein. DISCUSSION We isolated a human liver glucokinase cDNA (hLGLK1) of 2548 bases exclusive of poly(A) residues, which appeared to be full length as this size was consistent with the single 2.8-kb band seen on Northern blot analysis. If the initiator codon at 294 is the preferred translation start site (see below), this mRNA would encode a protein of 464 amino acids and an estimated molecular mass of 52 kDa. Of note is the fact that a fusion protein of hLGLK1 with glutathione S-transferase, expressed in bacteria, was a functional glucokinase enzyme (Y.T., unpublished work). A second form of glucokinase mRNA with a 124-nucleotide deletion was observed by PCR amplification of human liver cDNA. The hLGLK2 cDNA contained a predicted open reading frame of 1398 bp from an ATG codon at position 164, encoding a predicted protein of 466 residues, 98% identical to the rat enzyme, but different from the predicted protein of hLGLK1 cDNA by 16 aminoterminal residues. This mRNA is thought to occur by alternative splicing of a cassette exon between exons 1 and 2 in genomic DNA.
The rat liver glucokinase cDNA has been shown to be encoded by 10 exons within 15.5 kb of genomic DNA (11 identity with a comparable region (1-172 bp) of the rat cDNA (Fig. 4) . The next 124 bp in the human hLGLK1 cDNA have no homology with the rat cDNA. For human cDNAs the region comparable to that encoded by rat exons 2-10 has 88% sequence identity, and the 3'-untranslated region has 68% identity. An isoform of glucokinase cDNA was also described in rat liver with 151 bp of DNA between exons 1 and 2 shown to be due to alternative splicing of an additional cassette exon (15) . Although insertion of the 124-bp cassette exon in the human glucokinase (hLGLK1) cDNA occurred at the same site as insertion in the alternatively spliced rat liver enzyme, there was no sequence identity seen between the two insertions. Although hLGLK1 was the only clone we isolated from the cDNA library of 5 x iOs plaques, hLGLK2 seemed to be more abundant according to the result of the PCR amplification (Fig. 2) . In addition, the relative amount of the two forms seemed to vary among the individuals. Nevertheless, because of the difficulty in the quantification by PCR amplification, we cannot be certain about the relative abundance of these mRNAs. Whether nutritional and/or hormonal factors alter levels of the two forms of human glucokinase mRNA is also unknown. This question could be important for future studies, considering the potential physiological and pathological consequences, were the translated forms of glucokinase different in catalytic properties or stability.
Rat glucokinase has a single initiator codon followed by a long open reading frame (21) . Upstream ofthe ATG at 294 for hLGLK1 are six other ATG codons (Fig. 1, positions 94 (Fig. 3 ). Because these results were obtained in an in vitro system, the physiological relevance of this finding cannot be determined. Further, a full-length hLGLK2 cDNA clone was not isolated. Thus the determination of the relative level of expression of the two glucokinase enzymes in vivo awaits the development of specific antibodies and immunoblot analysis of liver protein.
The amino acid identities between rat and the human liver glucokinases were compared (Fig. 5) . For hLGLK1 there is almost no identity in the first 14 amino acids with the rat, whereas for hLGLK2 11/16 (69o) of the amino-terminal residues are identical; this is followed by an area with 97% amino acid identity in a region of 450-amino acid overlap. This comparison contrasts to 53% amino acid identity between rat glucokinase and the carboxyl-terminal region of rat brain hexokinase. The putative glucose-and ATP-binding domains were also highly conserved (12) .
As a consequence of isolating two human liver glucokinase cDNAs, the contribution of this gene to genetic susceptibility to non-insulin-dependent diabetes mellitus can now be assessed. The potential use of alternative promoters, as well as alternative splicing ofglucokinase mRNAs, makes the search for defects in the glucokinase genes of diabetic subjects an interesting one.
